Fall 2026

Strategy & Execution Co-op

Prostate

Posted on 8/13/2026

Deadline 8/26/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

CA$23 - CA$33/hr

Toronto, ON, Canada

Remote

Bachelor's, PharmD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Data Visualization
Word/Pages/Docs
Version Control
Pharmacology
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Available to work for the duration of the 12-month co-op term.
  • Strong interest in pharmaceutical or biotechnology medical affairs, oncology, prostate cancer, scientific communications, or healthcare strategy.
  • Foundational understanding of clinical research, medical literature, and evidence-based scientific communication.
  • Proficiency with Microsoft Office applications, especially PowerPoint, Word, Excel, and Outlook.
  • Strong written and verbal communication skills.
  • Strong organizational skills, attention to detail, and ability to manage multiple priorities.
  • Ability to work independently and collaboratively in a cross-functional team environment.
  • Authorized to work in Canada on a full-time basis without the need for future sponsorship.
  • Remain actively enrolled in an academic program throughout the entire internship.
  • Available to work 37.5 hours during the entire internship.
  • Record of strong academic performance, with a recommended grade point average of 2.8 or above.
Responsibilities
  • Support execution of apalutamide medical affairs priorities, including prostate cancer scientific strategy, launch readiness, and cross-functional alignment.
  • Track, organize, and follow up on key deliverables across medical affairs workstreams.
  • Synthesize scientific and strategic information into concise summaries, trackers, and project updates for internal stakeholders.
  • Support development of materials that enable consistent scientific communication across internal teams and regional partners.
  • Capture meeting outputs and action items in meeting minutes for post-meeting distribution twice per month.
  • Assist with planning and execution of healthcare professional engagement activities, advisory boards, scientific exchange meetings, and related follow-up materials.
  • Prepare discussion guides, pre-read materials, insight-capture templates, and post-meeting summaries.
  • Organize and synthesize healthcare professional insights to inform medical strategy, content refinement, and future engagement planning.
  • Develop, refine, and format scientific slide decks, internal updates, and presentation materials.
  • Ensure consistency of scientific messaging, references, visual standards, and slide flow across materials.
  • Adapt complex scientific information into clear, concise formats for internal medical affairs audiences.
  • Collaborate with medical, agency, and cross-functional partners to incorporate feedback and maintain version control.
  • Support updates to scientific communication platform materials, including disease-state, product, and evidence-based content.
  • Organize references, review content for consistency, and maintain alignment across related communication resources.
  • Identify opportunities to improve the usability, clarity, and consistency of core scientific materials.
  • Contribute to internal tools and resources that help teams communicate scientific information consistently.
  • Develop and maintain frequently asked questions, objection handlers, and related medical communication resources.
  • Support One J&J voice deliverables by aligning content across internal stakeholders and ensuring consistent terminology, structure, and message flow.
  • Consolidate inputs from medical, regional, and cross-functional partners into clear draft materials for review.
  • Prepare concise response documents and internal summaries addressing anticipated scientific questions.
  • Support planning and execution activities for major oncology and urology congresses.
  • Assist with congress preparation materials, abstract and session tracking, competitive intelligence summaries, medical insights capture, and post-congress reports.
  • Prepare internal pre- and post-congress communication materials, including one-page summaries, slide updates, and key takeaways.
  • Coordinate congress-related deliverables across medical affairs and cross-functional teams.
  • Support social media and digital landscape analysis related to prostate cancer congresses, apalutamide, and relevant scientific topics.
  • Identify, organize, and summarize emerging themes, discussion trends, and scientific conversation topics from approved sources and tools.
  • Maintain scientific objectivity and avoid unsupported interpretation when summarizing external discussions.
  • Maintain project trackers, timelines, action logs, and meeting notes for assigned workstreams.
  • Coordinate with internal stakeholders to gather inputs, track feedback, and support completion of deliverables.
  • Handle scientific and business-sensitive information with professionalism, discretion, and accountability.
Desired Qualifications
  • PhD/PharmD candidate, graduate student, or recent graduate with academic experience in pharmacy, biomedical sciences, pharmacology, epidemiology, public health, medical sciences, or a related field.
  • Prior coursework, research, rotation, internship, or work experience in oncology, urology, medical affairs, clinical development, medical information, regulatory affairs, or medical communications.
  • Experience creating or refining slide decks, scientific summaries, or educational materials.
  • Familiarity with oncology terminology, clinical trial design, and common evidence-generation concepts.
  • Interest in prostate cancer, genitourinary oncology, launch readiness, congress strategy, or scientific communications.
  • Comfort working with digital tools, dashboards, social listening outputs, or structured trackers.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.

INACTIVE